Clinical trial NCT03611816: Biological Bank for Atrial Fibrillation and Stroke
Official title: Biological Bank for Studies Related to Atrial Fibrillation and Stroke
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Stroke
Atrial Fibrillation
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2018-08-02
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Atrial fibrillation patient Stroke patient Patient over 80

Brief summary: Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years.

According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted.

The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.


Eligibility criteria: Group 1a

* Inclusion Criteria :

  - AF history
* Exclusion Criteria :

  * No AF history
  * patient who didn't signed consent

Group 1b

* Inclusion Criteria :

  * AF history
  * Scheduled electrophysiological exploration or AF ablation
* Exclusion Criteria :

  * No AF history
  * pregnant women
  * patient who didn't signed consent

Group 1c

* Inclusion Criteria :

  * AF/AT history
  * Stroke history
* Exclusion Criteria :

  * No Stroke history
  * patient who didn't signed consent

Group 2

* Inclusion Criteria :

  * patient over 80
  * ECG: sinusal rhythm
  * TTE : no left atrial dilatation
* Exclusion Criteria :

  * atrial fibrillation history
  * TTE : Left atria \>25cm², \> 34m/m2), FEVG \< 50%
  * ECG : QRS \> 90 ms
  * cardiac pathologies (excepted hypertension and valvulopathies)
  * History of stroke and transient ischemic attack
  * patient who didn't signed consent

Group 3

* Inclusion Criteria :

  * cryptogenic stroke or transient ischemic attack history before 50 yo
  * No AF history
* Exclusion Criteria :

  * AF history
  * stroke or transient ischemic attack over 50 yo
  * patient who didn't signed consent

Primary outcomes:
measure: Quality of DNA sample
timeFrame: 1 day (the day of the storage)
measure: Quality of Plasma sample
timeFrame: 1 day (the day of the storage)
measure: Quality of preservation of the sample
timeFrame: 7 years (during all the duration of the collection)
Secondary outcomes:
Other outcomes:
Locations:
city: Bourg-en-Bresse
country: France
facility: Service neurologie Centre hospitalier Fleyriat
city: Bron
country: France
facility: Service d'urgences Neurovasculaires - service de neurologie vasculaire , Hôpital Pierre Wertheimer
city: Bron
country: France
facility: Service de rythmologie, hôpital cardiologique Louis Pradel
city: Pierre-Bénite
country: France
facility: Service de médecine gériatrique Centre hospitalier Lyon Sud, Groupement hospitalier Sud
city: Villeurbanne
country: France
facility: Hôpital des charpennes
Study officials:
References: